SAR448501

DRUG2 trials

Sponsors

Sanofi

Conditions

B-cell Non Hodgkin LymphomaRheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)

Phase 1

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

RecruitingNCT06392477

SanofiB-cell Non Hodgkin Lymphoma

Start: 2024-07-08End: 2028-02-11Target: 96Updated: 2025-12-23

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

RecruitingNCT06647069

SanofiRheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)

Start: 2025-03-27End: 2029-06-25Target: 62Updated: 2026-09-09